Focus Reports releases its new 70 page Turkey Healthcare and Life Sciences Report 2016.
It offers companies, investors, policymakers, and stakeholders with an interest in healthcare, pharmaceuticals, or life sciences insights into the Turkish pharmaceutical industry; an industry with a rich heritage currently striving to find the balance between fostering domestic growth and building stronger international partnerships.
It features interviews with senior executives from the major companies in Turkey and leaders of the country’s most important institutions, updated facts and figures on Turkey’s healthcare and pharma sectors, and an exclusive in-depth cover story, ‘Navigating the Crossroads’.
The report is an authoritative assessment of one of Turkey’s leading industries. Turkish pharma will continue receiving a great deal of investment in the years and decades ahead for the following reasons:
Geography – Turkey is the most politically stable country in the region; well positioned to supply populations across North Africa, the Middle East, the Balkans, and parts of Western and Central Asia.
Domestic Initiatives – The Turkish state has realized the importance of the pharma sector and is now actively promoting initiatives in domestic vaccine production, biotech, and high-cost treatments.
International Cooperation – Turkey has much to gain by working with the global industry in the globalized production of innovative products and greater participation in the R&D process for new medicines.
The Turkey Healthcare and Life Sciences Report 2016 includes features and articles on:
- The Turkish Healthcare System
- Drug Reimbursement Policies
- Raw Materials and Regulations
- Medical Devices
Interviews
- The report also includes interviews with:
- Mehmet Müezzinoğlu, Turkish Minister of Health
- Yadigar Gökalp İlhan, SGK
- Süha Taşpolatoğlu,, Abdi Ibrahim
- Peter Catalino, Novartis
- Şebnem Avşar Tuna, Novo Nordisk
- Murat Barlas, Liba Laboratories
Quotes:
“All citizens can now obtain reimbursed-medicines from every pharmacy, every citizen can build a relationship with a family doctor, and we have reached high standards for emergency healthcare services.” Mehmet Müezzinoğlu, Turkish Minister of Health
“By 2020, the [private healthcare] sector’s revenue will double to USD 20 billion” Cevat Sengül, OHSAD
“The future of local producers will lie in specialty products, OTC, and exports.” Erol Kiresepi, Santa Farma
“Economic growth is expected to continue … and Turkey continues to be the most stable country in the region …. investing in Turkey makes sense” Dilek Bayraktar, ARTED
